RxDoctor Payments DataLook up a doctor →

Otto Dueno, MD

Psychiatry · Dayton, OHNPI 1467447623

Payments from drug & device makers

$3,098,279in general payments, 2019–2025

Across 1,253 payments — averaging $2472.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$540K
  • Sage Therapeutics, LLC$526K
  • Sunovion Pharmaceuticals Inc.$407K
  • Hoffmann-la Roche Limited$225K
  • Janssen Research & Development, LLC$224K
  • Indivior Inc.$197K
  • plus $978K from 36 others
$4,876in research payments, 2019–2025

Across 2 payments — averaging $2437.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Orexo US, Inc.$5K

What the payments were for

  • Consulting fees$6,9389%
  • Speaking & faculty fees$54,84574%
  • Travel & lodging$2,9534%
  • Food & beverage$9,74113%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,098,279 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in Ohio.

See all psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$282,759
Medicare patients
335
Services billed
3,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate53$84,375
AuvelityDextromethorphan Hbr/Bupropion50$45,596
TrintellixVortioxetine Hydrobromide32$23,494
VraylarCariprazine Hcl18$23,026
RexultiBrexpiprazole12$15,713
Paliperidone ErPaliperidone25$13,843
Aripiprazole152$8,204
Lurasidone Hcl46$6,884
Ziprasidone Hcl12$6,147
Clozapine68$5,104
Asenapine Maleate19$5,103
Duloxetine Hcl134$4,565
Desvenlafaxine Succinate ErDesvenlafaxine Succinate59$4,216
Clonazepam313$3,563
Divalproex Sodium ErDivalproex Sodium36$3,128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$116,396$84,37553 claims
Axsome Therapeutics, Inc.Auvelity$630$45,59650 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$301$23,49432 claims
AbbVieVraylar$540,335$23,02618 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,043$15,71312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in Ohio.

Other psychiatry in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →